The US Food and Drug Administration has granted tentative approval to Dr. Reddy’s Laboratories for a generic version of Gilead Sciences' groundbreaking HIV prevention injection lenacapavir, marketed as Yetzugo. Dr. Reddy’s plans to ship the medication next month at an annual cost of $40 per person,